{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-24-000065","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.308970+00:00","generated_at":"2026-05-29T02:02:15.235721+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC","bullets":["ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.","Lung target lesion ORR 36% (3 partial, 1 complete response) and DCR 82%.","Treatment-emergent AEs mild to moderate; no Grade 4/5 events; outpatient administration feasible.","Protocol amended to add two combination cohorts (with anti-PD-1 ± chemo) for advanced NSCLC.","Enrollment ongoing; detailed results to be presented at future scientific meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-24-000065","json":"https://secwatch.observer/filing/0001711279-24-000065.json","markdown":"https://secwatch.observer/filing/0001711279-24-000065.md","text":"https://secwatch.observer/filing/0001711279-24-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000065/0001711279-24-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000065/krys-20241218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:02:15.235721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}